Our Team

Ian Dixon

PhD, MBA, MAICD

Dr Ian Dixon has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications.

Ian has been successful in translating technology challenges into valuable businesses and respected intellectual property.

Ian is a co-inventor of Exopharm’s LEAP manufacturing technology and a co-inventor of Fortrexo, part of Exopharm’s EEV pipeline.

Ian brings to Exopharm an extensive technical, commercial and entrepreneurial background.

Before founding Exopharm in 2013, Ian co-founded Cynata Inc, the owner of the Cymerus stem cell technology now being commercialised by ASX-listed clinical-stage Cynata Therapeutics Ltd (ASX:CYP).

He is also non-executive director of NYRADA Inc. (ASX:NYR), co-inventor of Nyrada PCSK9 inhibitor drug NYX-330, and founder and investor of Cardio Therapeutics Pty Ltd.

Ian was previously a founding director of Sydney-based Noxopharm Ltd (ASX:NOX) and non-executive director of Melbourne unlisted company Cell Therapies Pty Ltd.

Chris Baldwin

PhD

Dr Chris Baldwin received his PhD in Chemical Engineering from the University of Cambridge, while matriculated at Trinity College. Chris joined Exopharm in November 2019, bringing a wide range of global commercial experience to the company.

Most recently, Chris was responsible for Haemonetics’ largest and most profitable business unit across Asia Pacific, with P&L responsibilities from Taiwan to Pakistan. Previously responsible for all sales and marketing in Southeast Asia, Chris provided strategy leadership across Asia Pacific, including China.

Chris’ strategic focus and approach to management comes from his time at McKinsey and Company, where he served banking, pharmaceutical and NGO clients.

Healthcare became the focus of Chris’ career at New York Blood Center, where he was Executive Director for 8 years and responsible for the blood supply across the greater New York metropolitan area.

Alison Cook

MSc

Alison Cook has more than 30 years of management and leadership experience across the biopharmaceutical, diagnostic and health service sectors. She has held senior Operations Management and General Management roles across several divisions of CSL Ltd during the 13 years she was with the company, including flu vaccine and antivenom manufacture. Executive roles as COO and then CEO of Genetic Technologies Ltd and consulting in manufacturing operations, strategy and quality to biotechnology companies across Asia Pacific with Centre for Biopharmaceutical Excellence (CBE) have extended her experience.

Alison is Director at Centre for Biopharmaceutical Excellence Pty Ltd and Non-Executive Director at McPherson Ltd.